Jun 03, 2022
Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers
Jun 01, 2022
Immutep Global Webcast to Discuss TACTI-002 Data Presented at ASCO 2022
May 27, 2022
Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022
May 04, 2022
Immutep Presents New and Significant Data from the AIPAC Study
Apr 28, 2022
Immutep Quarterly Activities Report
